Laboratory diagnosis


The last plenary session (II) contained amongst others one talk dedicated to NGS technologies in AML: Time to use in clinical care? The speaker, Torsten Haferlach, has reviewed the standard diagnostic approaches in AML, the unmet needs and how WGS, WES, RNA seq and panel testing can address it, with an overview of future developments. Further into the subject of diagnosis improvement, Marc Carrier during the education session gave the participants essential tools to describe the rate of occult cancer detection following VTE, to select suitable occult cancer screening strategies and to discuss the associated risks.

Links to the library and multimedia

Click on the blocks below to read the full stories, view abstracts, presentations, webcasts and expert interviews.

Torsten Haferlach | NGS technologies in AML: Time to use in clinical care?

Marc Carrier | Screening for occult cancer in patients with unprovoked VTE

Alberto Orfao | Added value of blood monitoring of CTCs vs. bone marrow MRD in multiple myeloma